Session 3:

Lessons Learned from the PRO Consortium
Along the Path to PRO Instrument Qualification: Case Study

FIFTH ANNUAL
PATIENT-REPORTED OUTCOME (PRO) CONSORTIUM WORKSHOP

April 29 - 30, 2014 ■ Silver Spring, MD

Co-sponsored by

CRITICAL PATH INSTITUTE
FDA
The views and opinions expressed in the following slides are those of the individual presenters and should not be attributed to their respective organizations/companies, the U.S. Food and Drug Administration, the Critical Path Institute, the PRO Consortium, or the ePRO Consortium.

These slides are the intellectual property of the individual presenters and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. All trademarks are the property of their respective owners.
Agenda

• Introduction: *Risa Hayes* - 5 min, 

• The Rheumatoid Arthritis Working Group (RA WG) : *Co-chairs* – 15 min:
  – Brief overview of the RA WG,
  – August 28, 2012 Stakeholder Workshop,

• Panel Discussion - 30 min:
  – Theme 1: Defining the value of stakeholder engagement early in the process of PRO development,
  – Theme 2: Ensuring collaboration with the appropriate stakeholders

• General Discussion - 10 min.
Session Participants

Moderator
– Risa Hayes, PhD – Research Advisor, Global Patient Outcomes and Real World Evidence, Eli Lilly and Company

Presenters (RA WG co-chairs):
– Enkeleida Nikai, MSc – Senior Research Scientist, Global Patient Outcomes and Real World Evidence, Eli Lilly and Company
– April N. Naegeli, DrPH, MPH – Senior Research Scientist, Global Patient Outcomes and Real World Evidence, Eli Lilly and Company

Panelists
– Clifton O. Bingham III, MD – Director, Johns Hopkins Arthritis Center; Co-Director Rheumatic Disease Research Core Center; Associate Professor of Medicine, Divisions of Rheumatology and Allergy at Johns Hopkins University
– Ashley F. Slagle, MS, PhD – COA Qualification Scientific Coordinator and Endpoint Reviewer, SEALD, OND, CDER, FDA
– Amye L. Leong, MBA – President & CEO, Healthy Motivation; Spokesperson & Director of Strategic Relations, United Nations Bone and Joint Decade, the Global Alliance for Musculoskeletal Health
– Lee S. Simon, MD, FACP, FACR – Principal, SDG LLC
– Sarah Yim, MD – Supervisory Associate Director, Division of Pulmonary, Allergy, and Rheumatology Products (DPARP), OND, CDER, FDA
Agenda

• Introduction: *Risa Hayes* - 5 min,

• The Rheumatoid Arthritis Working Group (RA WG) : *Co-chairs* – 15 min:
  – Brief overview of the RA WG,
  – August 28, 2012 Stakeholder Workshop,

• Panel Discussion - 30 min:
  – Theme 1: Defining the value of stakeholder engagement early in the process of PRO development,
  – Theme 2: Ensuring collaboration with the appropriate stakeholders

• General Discussion - 10 min.
The RA WG was formed in March 2011 and is currently being co-chaired by Eli Lilly. Pharma industry members are representatives from Boehringer Ingelheim, Eli Lilly, GSK, Merck, Novo Nordisk, Takeda and UCB:

- feasibility document in 2010 → FDA feedback → pharma representatives voting in 2011,

Since it’s start – development of disease model, submission of scoping document and continuous efforts in raising awareness and involvement of experts and patients from OMERACT and other clinical societies,

Since December 2011 closer collaboration with OMERACT (cf. FDA’s feedback on the scoping document) → OMERACT representation within the RA WG: Dr (s). V. Strand and L. Simon,

Presentation of the RA Working Group at OMERACT 11: Suggested to have a workshop involving all stakeholders (May 2012),

Stakeholders workshop (August 28, 2012)
Path to the FDA Qualification

✓ Letter of Intent,

✓ Initial Briefing Package (Scoping document),

➢ Vendor Selection Stage:

• Content Validity Stage
  Step I: Qualitative Research
  Step II: Quantitative Research

• Submit exploratory endpoint qualification dossier to FDA,

• Psychometric Analysis Stage,

• Submit effectiveness endpoint qualification dossier to FDA
Objectives:

- **To identify RA-related concepts** best assessed through patient self-report that could be further investigated to determine their potential role in the documentation of treatment benefit in RA clinical trials,
- To convene **stakeholders** who could contribute experience, clinical evidence, or expertise in the measurement of treatment benefit in RA clinical trials, particularly in the field of PRO assessment

Identifying Stakeholders:

- Populations who would directly/indirectly be affected,
- Experts and academics,
- Regulatory Agencies,
- Key influencers,
- Sponsors,
Workshop Attendees

• RA patient representatives,

• Representatives from the FDA, including the Division of Pulmonary, Allergy, and Rheumatology Products (DPARP) and the Study Endpoints and Labeling Development (SEALD) team,

• Clinical experts, including representatives from the American College of Rheumatology (ACR), Outcome Measures in Rheumatology (OMERACT), and European League Against Rheumatism (EULAR),

• Representatives from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),

• Members of the PRO Consortium’s RA Working Group
Outcome of Workshop & Path Forward

• Consensus:
  • Most important unmet need in RA → **FATIGUE**
    • Qualification of PRO measure as secondary endpoint

• Path Forward:

  Collaborate with OMERACT
  • Show incremental benefit of fatigue beyond primary and secondary endpoints,
  • Sponsors to share existing RA clinical trial data for exploration of incremental value of fatigue,
  • Provide operational conceptual definition of concept fatigue,

  Revise Briefing Package & Submit to FDA
  • Submission of dossier to the FDA and if/once agreement reached launch qualitative phase
Agenda

• Introduction: *Risa Hayes* - 5 min,

• The Rheumatoid Arthritis Working Group (RA WG): *Co-chairs* – 15 min:
  – Brief overview of the RA WG,
  – August 28, 2012 Stakeholder Workshop,

• Panel Discussion - 30 min:
  – Theme 1: Defining the value of stakeholder engagement early in the process of PRO development,
  – Theme 2: Ensuring collaboration with the appropriate stakeholders

• General Discussion - 10 min.
Theme 1: Defining the value of stakeholder engagement early in the process of PRO development (1/2)

• Background: How the stakeholder consensus workshop was beneficial for the RA WG - position of the RA WG,

• Questions and discussion:

  – **WHEN**:
    • How early do you think academia/experts and patients should be involved by WGs during the PRO development (cf. in various WGs, the stakeholders are involved once the target concept for PRO development has been selected and agreed between the pharma industry/WGs and the FDA)?

    • What does the FDA think about having experts and patients included during the phase of development of the Scoping document?
Theme 1: Defining the value of stakeholder engagement early in the process of PRO development (1/2)

• Questions and discussion:

  – **HOW** :

  • How do you think this stakeholder engagement should be pursued: isolated event where advice is given or continued stakeholder collaboration:
  • Academia & experts: perspective
    – Background: In most of the other WGs, academia is involved in the form Advisory panel (consulted at time of important steps), what is unique to the RA WG is that the FDA recommended the collaboration with the OMERACT (they are part of RA WG member and have also a contract in place with the RA WG to perform the preliminary work of defining the incremental value of evaluating fatigue).
    – Question: What is your perspective on this collaboration, how academics should be best involved?
  • Patient perspective:
    – Background : Typically in the other WGs the patient perspective is captured during the qualitative interviews when the target concept is being explored
    – Question: Should the patients be involved at the very start of the WG conception? Should patients be part of the WG as advisors?
  • FDA perspective: how the SEALD and review division could provide advice on the steps we are following? Can FDA participate in the OMERACT/RA WG workshops where there will discussed the findings (cf. two F2F workshops have been planned),
Theme 2: Ensuring collaboration with the right stakeholders

• WHO SHOULD BE THE STAKEHOLDERS? :

Questions for all panelists:
  – What about involving other stakeholders (cf. interested in the findings from the PRO that will be developed):
    • HTA/payers?
    • EMA and other regulatory agencies (cf. currently advice given only by the FDA and content validity with only US patients)?
    • PICORI?
    • Other?

• Is the pharma industry adequately represented by having only the RA WG members.
Agenda

• Introduction: Risa Hayes - 5 min,

• The Rheumatoid Arthritis Working Group (RA WG) : Co-chairs – 15 min:
  – Brief overview of the RA WG,
  – August 28, 2012 Stakeholder Workshop,

• Panel Discussion - 30 min:
  – Theme 1: Defining the value of stakeholder engagement early in the process of PRO development,
  – Theme 2: Ensuring collaboration with the appropriate stakeholders

• General Discussion - 10 min.
Session Participants

**Moderator**
- *Risa Hayes, PhD* – Research Advisor, Global Patient Outcomes and Real World Evidence, Eli Lilly and Company

**Presenters (RA WG co-chairs):**
- *Enkeleida Nikai, MSc* – Senior Research Scientist, Global Patient Outcomes and Real World Evidence, Eli Lilly and Company
- *April N. Naegeli, DrPH, MPH* – Senior Research Scientist, Global Patient Outcomes and Real World Evidence, Eli Lilly and Company

**Panelists**
- *Clifton O. Bingham III, MD* – Director, Johns Hopkins Arthritis Center; Co-Director Rheumatic Disease Research Core Center; Associate Professor of Medicine, Divisions of Rheumatology and Allergy at Johns Hopkins University
- *Ashley F. Slagle, MS, PhD* – COA Qualification Scientific Coordinator and Endpoint Reviewer, SEALD, OND, CDER, FDA
- *Amye L. Leong, MBA* – President & CEO, Healthy Motivation; Spokesperson & Director of Strategic Relations, United Nations Bone and Joint Decade, the Global Alliance for Musculoskeletal Health
- *Lee S. Simon, MD, FACP, FACR* – Principal, SDG LLC
- *Sarah Yim, MD* – Supervisory Associate Director, Division of Pulmonary, Allergy, and Rheumatology Products (DPARP), OND, CDER, FDA
Thank You!